Medicine and Dentistry
Proteochondroitin Sulfate
100%
Sorafenib
100%
Hepatocellular Carcinoma
100%
DNA Repair
100%
Metastatic Melanoma
100%
Melanoma
80%
Colony Formation
28%
Carcinoma Cell
28%
In Silico
28%
Phosphotransferase Inhibitor
24%
Cell Cycle
14%
Cell Cycle M Phase
14%
Programmed Cell Death
14%
Cell Viability
14%
Flow Cytometry
14%
Neutral Red
14%
Hepatocellular Carcinoma Cell Line
14%
Cell-Cycle Analysis
14%
In Vitro
14%
Systemic Therapy
14%
Overall Survival
14%
Lactate Dehydrogenase
14%
Signal Transduction
14%
Mitosis
14%
Cytotoxicity
14%
Messenger RNA
14%
Skin Cancer
10%
Lentigo Maligna
10%
Superficial Spreading Melanoma
10%
Clinician
10%
Immune Response
10%
Tumor Antigen
10%
Protein Expression
10%
Side Effect
10%
Targeted Therapy
10%
Patient Characteristics
10%
Immunology and Microbiology
Sorafenib
100%
Cell Invasion
100%
Chondroitin Sulfate Proteoglycan
33%
Fluorescence Activated Cell Sorting
33%
Melanoma Cell Line
33%
MAPK Signaling
33%
Squamous Cell
12%
Monoclonal Antibody Therapy
12%
M14 Cell Line
12%
WM164 Cell Line
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Chondroitin Sulfate
100%
Gene Delivery
100%
Neutral Red
12%
Proteochondroitin Sulfate
10%
Long Term Exposure
10%